Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading well-being enhancement company Healthways (HWAY - Analyst Report) and ConnectiCare recently revealed a 3-year partnership to provide the SilverSneakers Fitness Program. Starting from Jan 1, 2013, SilverSneakers will be available to eligible enrollees of ConnectiCare VIP Medicare Advantage plans.
Headquartered in Farmington, Connecticut, ConnectiCare is a health plan. It is a subsidiary of EmblemHealth. The company provides a range of healthcare plans ranging from products for individuals to services for businesses. The National Committee for Quality Assurance ranks ConnectiCare in the highest 10% of health plans in the country.
The Healthways model encourages people to make favorable lifestyle changes that lead to enhanced well-being, reduced healthcare costs, improved performance and economic value for customers. The company has invested in technology platforms that provide scalable support for large populations. It has tie-ups with a large proportion of U.S. health plans and counts many millions of lives in its customer base.
Due to its unique scalable business model, Healthways shares may present a long-term investment opportunity, although it faces many challenges in the short term.
Healthways is the leader in a strategically critical and rapidly evolving part of the health care services market. Its fitness program (SilverSneakers) for seniors is available at over 15,000 centers across the U.S. and caters to over nine million eligible enrollees.
The SilverSneakers Fitness Program encourages older people to regularly exercise, thereby reducing healthcare expenses and enhancing well being. The program promotes positive changes in behavior by meshing social encounters with its fitness regimen. Healthways competes with Express Scripts Holding Company (ESRX - Analyst Report) among others.
Currently, Healthways retains a Zacks Rank #3 (Hold), which supports its Neutral recommendation for the long term.
Get the full Analyst Report on HWAY - FREE
Get the full Analyst Report on ESRX - FREE